| Entry |
|
|---|
| Name |
Olodaterol hydrochloride (JAN/USAN);
Striverdi respimat (TN) |
|---|
| Product |
|
|---|
| Formula |
C21H26N2O5. HCl
|
|---|
| Exact mass |
422.1609
|
|---|
| Mol weight |
422.9025
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Product (DG01058): | D10020<US> |
| Product (mixture): | D10744<JP/US> |
|
|---|
| Efficacy |
Bronchodilator, beta2-Adrenergic receptor agonist |
|---|
| Disease |
Chronic obstructive pulmonary disease [DS: H01714] |
|---|
| Comment |
Phenethylamine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03A ADRENERGICS, INHALANTS
R03AC Selective beta-2-adrenoreceptor agonists
R03AC19 Olodaterol
D10020 Olodaterol hydrochloride (JAN/USAN) <US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Bronchodilators, Sympathomimetic
Olodaterol
D10020 Olodaterol hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01455 beta-Adrenergic receptor agonist
DG01452 beta2-Adrenergic receptor agonist
DG01058 Olodaterol
D10020 Olodaterol hydrochloride
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG01058 Olodaterol
D10020 Olodaterol hydrochloride
DG01642 CYP2C9 substrate
DG01058 Olodaterol
D10020 Olodaterol hydrochloride
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG01058 Olodaterol
D10020 Olodaterol hydrochloride
DG03185 UGT1A7 substrate
DG01058 Olodaterol
D10020 Olodaterol hydrochloride
DG03188 UGT1A9 substrate
DG01058 Olodaterol
D10020 Olodaterol hydrochloride
DG03190 UGT2B7 substrate
DG01058 Olodaterol
D10020 Olodaterol hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRB2
D10020 Olodaterol hydrochloride (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10020
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10020
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10020
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01455 beta-Adrenergic receptor agonist
DG01452 beta2-Adrenergic receptor agonist
DG01058 Olodaterol
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG01058 Olodaterol
DG01642 CYP2C9 substrate
DG01058 Olodaterol
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG01058 Olodaterol
DG03185 UGT1A7 substrate
DG01058 Olodaterol
DG03188 UGT1A9 substrate
DG01058 Olodaterol
DG03190 UGT2B7 substrate
DG01058 Olodaterol
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 29
1 C5x C 11.1300 -18.6200
2 N1x N 11.1300 -17.2200
3 C8y C 12.3200 -16.5200
4 C8y C 13.5100 -17.2200
5 O2x O 13.5100 -18.6200
6 C1x C 12.3200 -19.3200
7 C8x C 12.3200 -15.1200
8 C8y C 13.5100 -14.4200
9 C8x C 14.7700 -15.1200
10 C8y C 14.7700 -16.5200
11 O5x O 9.8700 -19.3200
12 O1a O 13.5100 -13.0200
13 C1c C 15.9600 -17.2200
14 C1b C 17.1500 -16.5200
15 O1a O 15.9600 -18.6200
16 N1b N 18.3400 -17.2200
17 C1d C 19.5300 -16.5200
18 C1b C 20.7200 -17.2200
19 C8y C 21.9800 -16.5200
20 C1a C 18.8300 -15.3300
21 C1a C 20.2300 -15.3300
22 C8x C 21.9800 -15.1200
23 C8x C 23.1700 -14.4200
24 C8y C 24.3600 -15.1200
25 C8x C 24.3600 -16.5200
26 C8x C 23.1700 -17.2200
27 O2a O 25.6200 -14.4200
28 C1a C 26.8100 -15.1200
29 X Cl 26.6700 -19.5300
BOND 30
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 3 7 2
8 7 8 1
9 8 9 2
10 9 10 1
11 4 10 2
12 1 11 2
13 8 12 1
14 10 13 1
15 13 14 1
16 13 15 1 #Down
17 14 16 1
18 16 17 1
19 17 18 1
20 18 19 1
21 17 20 1
22 17 21 1
23 19 22 2
24 22 23 1
25 23 24 2
26 24 25 1
27 25 26 2
28 19 26 1
29 24 27 1
30 27 28 1
|
|---|
